Dr. Londei most recently was the chief executive officer of Gadeta. Previously, he was the chief development officer and chief medical officer of AnaptysBio (NASDAQ: ANAB), where he played a crucial role in the company’s transition from a preclinical phase to its successful IPO, and several rounds of financing as a clinical stage biopharmaceutical company. Prior to AnaptysBio, Dr. Londei held leadership roles at Novartis and Bristol-Myers Squibb, in charge of global teams for clinical development in transplantation, autoimmune and inflammatory disease areas. Over the 15 years in the pharma industry, Dr. Londei and his team brought more than a dozen of new molecular entities into clinical development, six of which have since entered the market. Before his move to the pharmaceutical industry, Dr. Londei was professor of medicine at Imperial College and University College London in the UK. From his academic tenure, he also brings his valuable expertise in human T lymphocyte and their role in pathology.
Dr. Londei received his M.D. from the Faculty of Medicine at University of Bologna and has conducted post-doctoral studies at Tumor Immunology Unit, London, UK. He was a key member of the team which pioneered the development of anti-TNF therapies while at the Kennedy Institute of Rheumatology (KIR) Faculty of Medicine Imperial College, London with professors Ravinder Maini and Marc Feldmann. He is a widely recognized world-class contributor in the field of inflammation and self-recognition by T lymphocytes.